OakChart

Vir Biotechnology Inc

VIRHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 12:40 PM ET

13.21+0.06 (0.46%)
2026-11-11 18:40 CET
Market cap
2,252.21 USD m
Revenue, TTM
302.80 USD m
Net income, TTM
-184.79 USD m
Free cash flow, TTM
-141.82 USD m
EPS diluted, TTM
-1.26
P/E
-
Compare

Price

VIR against its 20, 50 and 200-day averages
2050200beat
8.0010.0012.0014.004.4M8.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VIRclose 13.2120-day 11.3950-day 11.16200-day 9.7313.2152w high

8.1% under the 52-week high of 14.38 on 9 Nov 2026. 52-week low 5.32 on 19 Nov 2025. Last 15 sessions, 43.4% high to low

Profile

VIR
52-week range, 87% of the way up
5.3214.38

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

IndexRUT
Employees367
IPOOct 11, 2019
Beta1.71
ATR, 14d0.78
Rel volume0.47
Short float12.44%
Insider own20.77%
Inst own67.88%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.26B
Enterprise Value1.89B
Income-184.79M
Sales302.80M
Book/sh5.29
Cash/sh2.69
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees367
IPOOct 11, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S7.47
P/B2.50
P/C4.92
P/FCF-
EV/EBITDA-
EV/Sales6.25
Quick Ratio6.30
Current Ratio6.30
Debt/Eq0.10
LT Debt/Eq0.09
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.26
EPS next Y-2.36
EPS next Q-0.12
EPS this Y66.90%
EPS next Y-125.49%
EPS next 5Y14.43%
EPS past 3/5Y- -4.76%
Sales past 3/5Y-65.12% -2.14%
EPS Y/Y TTM65.40%
Sales Y/Y TTM1695.96%
EPS Q/Q51.58%
Sales Q/Q-178.33%
EarningsNov 04 AMC
EPS/Sales Surpr.26.01% -116.44%

Ownership

Insider Own20.77%
Insider Trans-0.02%
Inst Own67.88%
Inst Trans3.97%
ROA-17.34%
ROE-21.84%
ROIC-18.90%
Gross Margin96.27%
Oper. Margin-70.21%
Profit Margin-61.03%
SMA2016.00%
SMA5018.32%
SMA20035.76%
Trades-

Technical

Shs Outstand169.41M
Shs Float135.70M
Short Float12.44%
Short Ratio8.32
Short Interest16.87M
52W High14.38 -8.14%
52W Low5.32 148.31%
Volatility8.41% 6.22%
ATR (14)0.78
RSI (14)63.67
Beta1.71
Rel Volume0.47
Avg Volume2.03M
Volume491,664

Performance

Perf Week12.23%
Perf Month24.51%
Perf Quarter46.78%
Perf Half Y41.59%
Perf YTD119.07%
Perf Year131.35%
Perf 3Y50.28%
Perf 5Y-60.04%
Perf 10Y-
Recom1.11
Target Price23.38
Prev Close13.15
Price13.21
Change %0.46%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Feb 24, 2026UpgradeRRaymond JamesOutperform → Strong Buy$19+43.8%
Sep 03, 2025InitiatedEEvercore ISIOutperform$12-9.2%
Aug 27, 2025UpgradeBBofA SecuritiesNeutral → Buy$14+6.0%
Jan 29, 2024DowngradeJJP MorganOverweight → Neutral$23 → $9-31.9%
Sep 08, 2023DowngradeBBofA SecuritiesBuy → Neutral$23 → $14+6.0%
Mar 06, 2023UpgradeJJP MorganNeutral → Overweight$35 → $34+157.4%
Feb 21, 2023UpgradeGGoldmanNeutral → Buy$41 → $53+301.2%
Jan 27, 2023UpgradeMMorgan StanleyUnderweight → Equal-Weight$18 → $30+127.1%
Sep 14, 2022InitiatedSSVB LeerinkOutperform$40+202.8%
Sep 09, 2022InitiatedMMorgan StanleyUnderweight$15+13.6%

Peers

Mkt cap
TickerCompanyMkt cap
JANXJanux Therapeutics Inc768.47M
CTMXCytomX Therapeutics Inc459.66M
MIRMMirum Pharmaceuticals Inc6.13B
ASMBAssembly Biosciences Inc454.04M
ABUSArbutus Biopharma Corp764.68M
IMCRImmunocore Holdings plc ADR1.64B
XLOXilio Therapeutics Inc56.26M
ZYMEZymeworks BC Inc2.06B
GILDGilead Sciences Inc209.74B
ALGSAligos Therapeutics Inc16.49M

Insider trading

latest 14 of 66
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
de Verneuil VaninaEVP, General Counsel, Corp SecNov 03 '26Sale11.102,40726,718110,193Nov 04 02:56 PM
de Verneuil VaninaEVP, General Counsel, Corp SecNov 02 '26Sale11.331,34315,222112,600Nov 04 02:56 PM
de Verneuil VaninaOfficerNov 03 '26Proposed Sale11.102,40726,718Nov 03 10:15 AM
de Verneuil VaninaOfficerNov 02 '26Proposed Sale11.331,34315,222Nov 02 03:32 PM
O'Byrne JasonFormer OfficerSep 17 '26Proposed Sale11.0019,357212,927Sep 17 10:15 AM
O'Byrne JasonFormer OfficerSep 09 '26Proposed Sale11.1328,333315,241Sep 09 10:57 AM
O'Byrne JasonFormer OfficerAug 25 '26Proposed Sale10.4823,148242,591Aug 25 11:07 AM
O'Byrne JasonFormer OfficerAug 24 '26Proposed Sale9.9014,352142,124Aug 24 05:11 PM
O'Byrne JasonFormer OfficerAug 21 '26Proposed Sale9.8125,000245,297Aug 21 03:24 PM
Ramasastry SairaFormer DirectorJun 29 '26Proposed Sale10.3216,000165,139Jun 29 03:06 PM
Napolitano JanetDirectorJun 01 '26Sale9.453,20030,24021,216Jun 02 05:35 PM
Sabatini BrentSVP, Chief Accounting OfficerJun 01 '26Sale9.453793,58261,902Jun 02 05:31 PM
Sabatini BrentOfficerJun 01 '26Proposed Sale9.453793,582Jun 01 03:03 PM
Napolitano JanetDirectorJun 01 '26Proposed Sale9.453,20030,240Jun 01 01:04 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
DFASU.S. Small Cap Portfolio-ETF Class Shares-

News

latest 14 of 206
  • Vir Biotechnologys hepatitis D drug scores in Phase II and Phase III trials (Clinical Trials Arena)
  • Vir hepatitis D drug succeeds in first pivotal study (BioPharma Dive) +11.75%
  • Vir Biotechnology Shares Rise 22% as Phase 3 Hepatitis Delta Trial Meets Primary and Secondary Endpoints (InvestorsHub)
  • Vir Biotechnology stock jumps 22% after hepatitis delta Phase 3 trial success (Investing.com)
  • VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets (Stocktwits)
  • Loading…
  • Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week? (Stocktwits)
  • Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data (Business Wire)
  • Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta (Business Wire)
  • Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLDs The Liver Meeting 2026 and Host Investor Conference Call (Business Wire) -6.37%
  • Vir Biotechnology Beats On A Narrower Loss, But ECLIPSE 1 Will Decide The Story (Earnings Whispers)
  • Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results (Business Wire)
  • Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference (Business Wire)
  • Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.570-0.770-0.570-0.191.148
2026Q22026-08-050.4700.3330.474238.95135.8810
2026Q12026-05-06-0.850-0.096-0.853-0.0355.4910
2025Q42026-02-23-0.310-0.491-0.30864.0719.919
2025Q32025-11-05-1.170-0.844-1.1740.241.989
2025Q22025-08-06-0.800-0.723-0.8011.212.728
2025Q12025-05-07-0.880-0.836-0.8803.038.597
2024Q42025-02-26-0.760-0.872-0.76512.378.178
2024Q32024-10-31-1.560-1.053-1.5642.385.548
2024Q22024-08-01-1.020-0.895-1.0163.087.538
2024Q12024-05-02-0.480-1.051-0.48356.3811.717
2023Q42024-02-22-0.860-1.008-0.86216.7911.189
2023Q32023-11-02-1.220-1.207-1.2172.648.719
2023Q22023-08-03-1.450-1.203-1.4533.8022.399
2023Q12023-05-04-1.060-0.875-1.05562.9650.159
2022Q42023-02-23-0.760-0.348-0.76349.41149.618

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-5.760-1.835-1.6238.099.15
2020FY-2.510-2.386-2.50676.3779.35
2021FY3.9602.7043.9611,095905.58
2022FY3.8304.3133.8261,6161,713
2023FY-4.590-4.660-4.58686.1879.68
2024FY-3.830-3.882-3.83174.2168.66
2025FY-3.160-3.355-3.16068.5620.80
2026FY--1.046--330.43
2027FY--2.359--71.74
2028FY--1.980--100.93
2029FY--1.527--203.54
2030FY--0.963--328.27

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0976187.440.11305
2026Q4S2026-11-0675287.440.10305
2026Q4S2026-11-0563141.050.1090.00
2026Q4S2026-11-047016.290.0119.80
2026Q4S2026-10-297016.290.0119.80
2026Q4S2026-10-218015.500.0119.80
2026Q4S2026-10-208125.500.0119.80
2026Q4S2026-10-138235.500.0119.80
2026Q4S2026-08-078225.510.0119.80
2026Q4S2026-08-068115.360.0120.64
2026Q4S2026-07-218005.240.0120.64
2026Q4S2026-05-178145.240.0120.64
2026Q4S2026-05-108155.240.0120.64
2026Q4S2026-05-078255.240.0120.64

Estimate history

EPS, annual-0.637-1.057-1.623-2.5063.9613.826-4.586-3.831-3.162-1.2557
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.564-0.765-0.88-0.801-1.174-0.308-0.8530.474-0.569
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.70810.6688.09176.3681095.4151615.79786.1874.20568.556302.8
Period201720182019202020212022202320242025TTM
Sales, quarterly2.3812.3743.0321.2140.2464.07-0.029238.946-0.188
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual110.469110.469107.649127.417131.161133.237134.781136.959139.475169.414
Period201720182019202020212022202320242025MRQ
Shares, quarterly136.706136.959138.064138.886139.023139.475161.234169.186169.414
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue302.8068.5674.2086.181,615.801,095.4176.378.0910.67
Cost of Goods Sold Incl. D&A11.3111.7115.4022.22161.8171.68---
Gross Profit291.4956.8558.8063.961,453.991,023.74---
Selling, General and Administrative Excl. Other504.09524.87582.22724.97620.92602.99363.70177.07126.60
Research and Development402.51432.80463.19550.92467.87442.19296.14139.4797.47
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-212.60-468.02-523.42-661.00833.07420.75-296.15-173.50-118.69
Interest Expense0.000.000.000.000.00---0.00
Unusual Expense3.719.5869.2745.19111.14-138.050.839.23-
Net Income Before Taxes-184.72-437.77-523.11-628.19754.28549.80-298.61-174.53-116.36
Income Taxes0.070.22-1.15-13.08238.4421.220.050.15-0.48
Consolidated Net Income-184.79-437.99-521.96-615.12515.84528.58-298.67-174.68-115.88
Net Income From Continuing Operations-184.79-437.99-521.96-615.06515.84528.58-298.67-174.68-115.88
Net Income-184.79-437.99-521.96-615.06515.84528.58-298.67-174.68-115.88
EPS (Recurring)-1.08-3.11-3.48-4.354.403.24-2.50-1.56-1.06
EPS (Basic, Before Extraordinaries)-1.25-3.16-3.83-4.593.894.07-2.51-1.62-1.06
EPS (Diluted)-1.26-3.16-3.83-4.593.833.96-2.51-1.62-1.06
EBITDA-201.32-456.34-508.86-641.55848.56432.73-287.33-168.98-115.94
Non-Operating Income (Expense)31.5939.8369.5978.0032.35-9.00-1.638.202.33
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense36.4538.7761.9887.9480.6461.1620.156.363.99
Price To Earnings Ratio----2.9810.77---
Price To Sales Ratio6.2512.1813.4815.662.115.1041.79167.31-
Gross Margin96.2782.9279.2474.2289.9993.46---
Operating Margin-70.21-682.68-705.37-767.0151.5638.41-387.79-2,144.35-1,112.60
Net Margin-61.03-638.87-703.40-713.6931.9248.25-391.09-2,158.98-1,086.28
Shares Outstanding169.41139.47136.96134.78133.24131.16127.42107.65110.47
Market Capitalization2,252.212,252.211,010.861,353.283,369.175,479.953,411.481,379.211,329.31

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue-0.19238.95-0.0364.070.241.213.0312.37
Cost of Goods Sold Incl. D&A2.772.802.812.922.992.932.873.57
Gross Profit-2.96236.14-2.8461.15-2.75-1.710.178.80
Selling, General and Administrative Excl. Other103.06161.55130.34109.15170.14106.89138.69108.36
Research and Development78.63131.35107.0085.53147.9184.61114.7581.66
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-106.0274.60-133.18-48.00-172.88-108.61-138.53-99.55
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.952.85-0.722.53-0.7813.19-5.3618.77
Net Income Before Taxes-96.3980.26-125.53-43.06-162.97-110.79-120.95-104.67
Income Taxes-0.140.180.17-0.140.170.170.02-0.09
Consolidated Net Income-96.2580.08-125.69-42.92-163.14-110.96-120.97-104.59
Net Income From Continuing Operations-96.2580.08-125.69-42.92-163.14-110.96-120.97-104.59
Net Income-96.2580.08-125.69-42.92-163.14-110.96-120.97-104.59
EPS (Recurring)-0.570.49-0.86-0.30-1.18-0.73-0.91-0.67
EPS (Basic, Before Extraordinaries)-0.570.48-0.85-0.31-1.17-0.80-0.88-0.76
EPS (Diluted)-0.570.47-0.85-0.31-1.17-0.80-0.88-0.76
EBITDA-103.2577.40-130.37-45.10-169.88-105.69-135.66-96.67
Non-Operating Income (Expense)8.678.526.937.479.1311.0112.2213.65
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.269.799.558.858.979.8411.1112.48
Price To Sales Ratio6.255.6820.1612.2547.0536.7342.7013.53
Gross Margin1,573.4098.839,793.1095.44-1,144.58-141.195.4471.15
Operating Margin56,392.5531.22459,241.38-74.92-72,034.58-8,946.38-4,568.83-804.54
Net Margin51,197.8733.51433,431.03-66.99-67,975.42-9,139.87-3,989.61-845.23
Shares Outstanding169.41169.19161.23139.47139.02138.89138.06136.96
Market Capitalization2,252.211,718.561,431.91838.92793.21696.72888.691,010.86

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments468.94994.731,535.682,414.72716.74744.85389.62109.20187.92
Short Term Receivables3.605.1011.600.00773.080.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets41.5442.6240.95104.3673.0027.5113.388.584.43
Total Current Assets514.081,042.461,588.232,519.081,562.82772.37403.00117.78192.35
Net Property, Plant & Equipment117.72122.86167.20188.17130.0579.8916.3112.295.14
Total Investments and Advances321.54196.38111.7230.58208.3912.6238.197.671.00
Intangible Assets24.7925.0639.5049.6950.2250.7652.6353.8552.82
Deferred Tax Assets22.1124.7741.03249.7296.85----
Other Assets24.7012.0612.4114.572.773.131.950.000.26
Total Assets1,024.931,423.591,960.093,051.812,051.12918.76512.07191.60251.57
Short Term Debt Incl. Current Port. of LT Debt8.807.7512.874.143.933.890.240.000.00
Accounts Payable9.805.086.336.426.525.085.886.474.90
Income Tax Payable--0.1515.236.22----
Other Current Liabilities74.21106.83156.06485.24324.5890.1053.0933.447.54
Total Current Liabilities92.81119.66175.41511.03341.2499.0659.2139.9112.44
Long Term Debt89.0590.14111.67123.84133.5667.260.900.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities22.1124.7743.22252.98115.293.253.313.313.31
Other Liabilities55.6838.6339.5586.0129.1832.3424.7218.4212.21
Total Liabilities259.65273.20369.85973.85619.27201.9188.1361.6427.96
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00309.14292.52
Common Equity765.281,150.381,590.242,077.961,431.85716.85423.94-179.18-68.92
Total Shareholders Equity765.281,150.381,590.242,077.961,431.85716.85423.94129.96223.61
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity765.281,150.381,590.242,077.961,431.85716.85423.94129.96223.61
Total Liabilities & Stockholders Equity1,024.931,423.591,960.093,051.812,051.12918.76512.07191.60251.57
Book Value Per Share5.498.4011.8015.6010.925.633.94-1.62-0.62
Tangible Book Value Per Share5.318.2211.5115.2210.535.233.45-2.11-1.10
Full-Time Employees367408587576444327229--
Price to Book Ratio2.490.810.811.573.844.763.19-4.73-
Return on Assets-35.78-30.85-24.5420.2235.60-41.75-49.65-52.30-
Return on Equity-45.73-38.09-33.5329.3949.20-52.36-63.07-65.55-
Return on Invested Capital-51.27-42.08-36.1423.4333.77-38.09-41.12-89.17-31.24
Quick Ratio5.548.719.054.934.587.806.812.9515.46
Current Ratio5.548.719.054.934.587.806.812.9515.46

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-184.79-437.99-521.96-615.12515.84528.58-298.67-174.68-115.88
Depreciation11.2811.6814.5619.4515.4911.988.814.522.76
Other Funds (Non Cash)57.3556.97148.00122.53481.7425.0569.4432.337.02
Funds from Operations-116.16-369.33-362.35-474.19997.89580.80-220.46-137.84-106.59
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-24.86-22.45-84.01-304.59665.37-628.3929.528.2012.49
Cash from Operating Activities-141.02-391.78-446.35-778.781,663.25-47.59-190.94-129.63-94.10
Capital Expenditures-0.80-4.83-7.30-21.57-68.03-21.82-6.55-8.94-9.94
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.110.253.370.100.020.000.180.000.03
Purchase or Sale of Investments-53.18314.95503.30186.20-1,125.45-119.00-3.49-247.22-50.53
Purchase of Investments-894.78-886.33-1,235.34-2,016.19-1,476.96-420.24-403.84-643.90-123.11
Sale Or Maturity of Investments841.601,201.281,738.632,202.39351.51301.24400.35396.6872.57
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-54.10310.37499.37164.73-1,193.46-140.81-9.86-256.16-60.44
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock243.574.154.557.7736.22100.59533.97444.8824.98
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock243.574.154.557.7736.22100.59533.97444.8824.98
Proceedsfrom Stock Options240.322.803.764.2831.6887.51529.91443.7524.39
Issuance or Reduction of Debt, Net-0.36-0.36-0.17-0.29-0.26-0.26-0.254.370.00
Change in Long Term Debt-0.36-0.36-0.17-0.29-0.26-0.26-0.254.370.00
Issuance of Long Term Debt0.000.000.000.000.000.000.004.470.00
Reduction of Long Term Debt-0.36-0.36-0.17-0.29-0.26-0.26-0.25-0.100.00
Net Financing Active Other Cash Flow0.360.000.00-0.10-1.200.00-4.25-0.000.00
Other Financing Activities Uses0.360.000.00-0.10-1.200.00-4.25-0.000.00
Cash from Financing Activities243.573.794.397.3834.76100.33529.47449.2424.98
Net Change in Cash48.46-77.6257.40-606.68504.55-88.07328.6763.45-129.56
Free Cash Flow-141.82-396.61-453.65-800.361,595.22-69.41-197.49-138.57-102.29
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Price to Free Cash Flow----2.14----
Deferred Taxes & Investment Tax Credit-0.00-2.95-1.06-15.1915.19-0.050.00-0.48

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments460.29534.65478.22468.94508.73694.24
Short Term Receivables17.3013.703.303.604.005.20
Inventories0.000.000.000.000.000.00
Other Current Assets30.6825.3841.4641.5432.9636.27
Total Current Assets508.27573.74522.99514.08545.68735.71
Net Property, Plant & Equipment105.76109.82113.92117.72121.76125.65
Total Investments and Advances449.85481.96339.93321.54311.17293.06
Intangible Assets24.5724.6424.7124.7924.8624.93
Deferred Tax Assets---22.11--
Other Assets23.4124.6524.0424.7015.9813.19
Total Assets1,111.861,214.811,025.591,024.931,019.451,192.53
Short Term Debt Incl. Current Port. of LT Debt9.329.148.948.808.968.82
Accounts Payable11.3217.755.459.806.8512.23
Other Current Liabilities60.0268.0759.1774.2159.4183.94
Total Current Liabilities80.6694.9673.5692.8175.22105.00
Long Term Debt81.4684.1486.6489.0591.2293.41
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---22.11--
Other Liabilities53.7053.2252.6355.6856.9246.65
Total Liabilities215.82232.31212.82259.65223.35245.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity896.04982.49812.76765.28796.10947.47
Total Shareholders Equity896.04982.49812.76765.28796.10947.47
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity896.04982.49812.76765.28796.10947.47
Total Liabilities & Stockholders Equity1,111.861,214.811,025.591,024.931,019.451,192.53
Book Value Per Share5.295.815.045.495.736.82
Tangible Book Value Per Share5.145.664.895.315.556.64
Full-Time Employees---367--
Price to Book Ratio2.492.021.631.050.840.67
Return on Assets-17.34-20.91-37.95-35.78-39.69-38.45
Return on Equity-21.84-26.08-47.69-45.73-49.06-46.22
Return on Invested Capital-9.857.51-13.98-5.02-18.39-10.66
Quick Ratio6.306.047.115.547.257.01
Current Ratio6.306.047.115.547.257.01

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-96.2580.08-125.69-42.92-163.14-110.96
Depreciation2.772.802.812.903.002.92
Other Funds (Non Cash)10.2016.9813.1816.9913.1712.88
Funds from Operations-83.2899.86-109.70-23.03-146.97-95.16
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-22.8023.47-22.68-2.84-20.60-25.06
Cash from Operating Activities-106.08123.33-132.39-25.88-167.57-120.22
Capital Expenditures-0.03-0.03-0.39-0.35-0.32-2.54
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00-0.110.040.04
Purchase or Sale of Investments44.59-197.1112.2287.1140.7358.95
Purchase of Investments-128.48-352.10-158.37-255.82-264.45-192.37
Sale Or Maturity of Investments173.08154.99170.60342.93305.17251.32
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities44.56-197.1411.8486.6540.4556.46
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.6378.38162.521.040.102.41
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.6378.38162.521.040.102.41
Proceedsfrom Stock Options0.0076.94162.351.040.001.76
Issuance or Reduction of Debt, Net0.000.000.00-0.360.000.00
Change in Long Term Debt0.000.000.00-0.360.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.360.000.00
Net Financing Active Other Cash Flow0.000.000.000.360.00-0.36
Other Financing Activities Uses0.000.000.000.360.00-0.36
Cash from Financing Activities1.6378.38162.521.040.102.05
Net Change in Cash-59.894.5641.9761.81-127.02-61.72
Free Cash Flow-106.11123.29-132.78-26.22-167.89-122.76

Revenue breakdown

Grant2024: 10.49M 2025: 2.04M
License And Collaboration2024: 61.37M 2025: 63.13M
Other2024: 2.34M 2025: 3.39M
Non-US2024: 62.68M 2025: 66.52M
United States2024: 11.53M 2025: 2.04M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.44%16.9M135.7M1.91M
2026-10-1512.11%16.2M134.1M1.94M
2026-09-3011.17%15.0M134.1M1.80M
2026-09-1514.66%19.7M134.1M1.97M
2026-08-3115.93%21.3M134.0M1.87M
2026-08-1414.63%19.6M134.0M1.83M
2026-07-3114.24%19.0M133.7M1.85M
2026-07-1513.84%18.5M133.3M1.87M
2026-06-3014.40%19.2M133.3M1.93M
2026-06-1513.57%18.1M133.3M1.78M
2026-05-2913.74%18.3M133.3M2.22M
2026-05-1512.77%16.8M131.8M3.46M
2026-04-3013.27%16.1M121.5M3.48M
2026-04-1514.61%16.8M115.1M3.57M
2026-03-3115.48%16.8M108.8M3.57M
2026-03-1314.20%15.4M108.8M3.49M
2026-02-2714.40%13.7M95.0M3.09M
2026-02-1313.46%12.8M95.0M1.82M
2026-01-3013.00%12.2M94.1M1.80M
2026-01-1512.75%12.0M94.1M1.73M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.0010.1012.600.0018.9270.000.000.992-0.0160.000
call3.009.2011.500.0012.8680.000.000.989-0.0170.001
call4.008.4011.509.4214.5315.000.000.986-0.0170.001
call5.006.009.500.008.4570.000.000.983-0.0170.001
call6.006.208.500.007.1180.000.000.980-0.0160.001
call7.004.807.700.006.4810.000.000.975-0.0160.001
call8.004.206.400.004.9230.000.000.970-0.0150.001
call9.003.205.402.514.1512.000.000.962-0.0150.002
call10.002.204.103.802.9385110.000.952-0.0140.002
call11.001.702.652.081.7205600.000.838-0.0370.005
call12.000.901.851.101.44551822.000.748-0.0400.007
call13.000.451.000.701.0724020.000.575-0.0600.008
call14.000.050.750.401.28376.000.000.459-0.0730.008
call15.000.100.250.101.0042481.000.225-0.0350.006
call16.000.000.200.231.1783130.000.168-0.0340.005
call17.000.000.750.051.4302.000.000.146-0.0370.005
call18.000.000.050.081.3504230.000.085-0.0240.003
call19.000.000.750.001.3390.000.000.047-0.0150.002
put2.000.000.050.006.0290.000.00-0.008-0.0150.000
put3.000.000.750.006.9200.000.00-0.029-0.0520.001
put4.000.000.750.005.6290.000.00-0.037-0.0520.002
put5.000.002.000.003.7310.000.00-0.027-0.0270.001
put6.000.000.750.003.0900.000.00-0.033-0.0260.002
put7.000.000.050.052.55519.000.00-0.040-0.0250.002
put8.000.000.400.201.8346.000.00-0.031-0.0150.001
put9.000.000.750.351.4521.000.00-0.038-0.0140.002
put10.000.000.050.041.2775040.00-0.078-0.0210.003
put11.000.050.250.851.31041.000.00-0.159-0.0360.005
put12.000.000.350.200.99814.000.00-0.266-0.0390.007
put13.000.150.650.621.4773.001.00-0.426-0.0590.008
put14.000.702.701.002.6780.000.00-0.551-0.0700.008
put15.001.702.750.001.9580.000.00-0.772-0.0330.006
put16.001.903.700.002.2420.000.00-0.830-0.0320.005
put17.002.904.700.002.4010.000.00-0.854-0.0350.005
put18.003.905.500.002.4880.000.00-0.947-0.0120.002
put19.004.906.800.002.7730.000.00-0.952-0.0130.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-098-KCurrent report2026-11-08SEC
2026-11-06SCHEDULE 13D/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-11-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-283Initial statement of beneficial ownership of securities2026-10-27SEC
2026-10-288-KCurrent report2026-10-26SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-148-KCurrent report2026-10-09SEC
2026-10-088-KCurrent report2026-10-08SEC
2026-10-063Initial statement of beneficial ownership of securities2026-10-05SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-07SCHEDULE 13GSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-248-KCurrent report2026-07-20SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-103Initial statement of beneficial ownership of securities2026-06-09SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110041.94K2
2026-100000
2026-090000
2026-080000
2026-070000
2026-060033.82K2
2026-0500221.03K1
2026-0400863.97K2
2026-0300279.51K2
2026-02001.18M15
2026-0100130.38K1
2025-12001.28M2
2025-11004.30M8

Institutional holders

Manager% owned
BlackRock, Inc.12.26%
ARCH Venture Management, LLC7.53%
VANGUARD PORTFOLIO MANAGEMENT LLC6.82%
SB INVESTMENT ADVISERS6.49%
STATE STREET CORP5.91%
GSK plc5.05%
VANGUARD CAPITAL MANAGEMENT LLC3.79%
Point72 Asset Management, L.P.3.36%
DIMENSIONAL FUND ADVISORS LP1.96%
GEODE CAPITAL MANAGEMENT, LLC1.78%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF4.34%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.93%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.87%
VANGUARD SMALL-CAP INDEX FUND2.06%
iShares Russell 2000 ETF1.87%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.18%
VANGUARD STRATEGIC EQUITY FUND1.04%
VANGUARD EXTENDED MARKET INDEX FUND0.83%
Fidelity Small Cap Index Fund0.80%
iShares Russell 2000 Value ETF0.68%

OakChart. VIR. Cached 15 minutes.